Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations

被引：0

作者：

Mok, T. S. K. ^{[1
]}

Cheng, Y. ^{[2
]}

Zhou, X. ^{[3
]}

Lee, K. H. ^{[4
]}

Nakagawa, K. ^{[5
]}

Niho, S. ^{[6
]}

Linke, R. ^{[7
]}

Rosell, R. ^{[8
]}

Corral, J. ^{[9
]}

Migliorino, M. R. ^{[10
]}

Pluzanski, A. ^{[11
,12
]}

Noonan, K. ^{[13
]}

Tang, Y. ^{[14
]}

Wilner, K. D. ^{[14
]}

Wu, Y-L. ^{[15
,16
]}

机构：

[1] Prince Wales Hosp, Clin Oncol, Hong Kong, Peoples R China

[2] Jilin Prov Canc Hosp, Changchun, Jilin, Peoples R China

[3] Third Mil Med Univ, Affiliated Hosp 1, Dept Resp Med, Chongqing, Peoples R China

[4] Chungbuk Natl Univ, Coll Med, Chungbuk Natl Univ Hosp, Cheongju, South Korea

[5] Kindai Univ Hosp, Osaka, Japan

[6] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan

[7] SFJ Pharmaceut, Pleasanton, CA USA

[8] Catalan Inst Oncol, Barcelona, Spain

[9] Hosp Univ Virgen del Rocio, Seville, Spain

[10] San Camillo Forlanini Hosp, Pulm Oncol Unit, Rome, Italy

[11] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[12] Inst Oncol, Warsaw, Poland

[13] Pfizer Inc, Groton, CT 06340 USA

[14] Pfizer Oncol, La Jolla, CA USA

[15] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China

[16] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA19

引用

页数：2